Non papillary mini-percutaneous nephrolithotomy: early experience.

PURPOSE: This study aims to evaluate the non-papillary puncture for mini-PCNL in terms of safety and efficacy. METHODS: A total number of 32 patients were subjected to mini-PCNL by the performance of non-papillary punctures over 6 months. One-step track dilation to 22 Fr took place in all cases. An 18 Fr nephroscope (Slender, Karl Storz GmbH, Germany) and an ultrasound lithotripter (Lithoclast Master, EMS S.A, Switzerland) with 9.9 Fr probe was used. Demographics and perioperative data are prospectively collected from an institutional board-approved database and the presented data were retrospectively collected. RESULTS: The average cumulative stone size was 23.53 ± 6.6 mm. Mean operative time was 44.6 ± 13.44 min and primary stone-free rate after PCNL was 96% and 85.7% for single and multiple access, respectively. Second access was performed in seven cases, all of which had multiple stones. Mean hemoglobin drop was 1.23 ± 0.88 gr/dL. The patients stayed 2.56 ± 0.98 days in the hospital. Overall complication rate was 9.37%, without encountering any severe bleeding complication. CONCLUSION: Using non-papillary access for mini-PCNL did not result in significant blood loss and need for transfusions. The respective data were directly comparable to contemporary literature and the safety of mini-PCNL by a non-papillary approach could be advocated.

Drug eluting stent in urology.

The Drug eluting stents (DESs) are the most commonly used stents in interventional cardiology. DESs have been shown to minimize the restenosis rate after stenting the coronary vessels by addressing the phenomena of smooth muscle proliferation and inflammation. The effect of the DESs is attributed to the antiproliferative drugs which are coated onto the stent and are released in controlled fashion. The anti-proliferative drugs reduce the hyperplastic reaction by inhibiting the smooth muscle cell cycle and their proliferation. Urological stents are important instruments of the everyday urological practice with a variety of indications for their use. Nevertheless, their use is hampered by a number of complications such as infection, patient discomfort, encrustation, migration and hyperplastic reaction. In an attempt to reduce the complications, the concept of DESs was introduced to Urology. DESs for ureteral or urethral as well as polymeric or metal have been evaluated in experimental studies. The clinical evaluation of DESs is limited only to polymeric stent with results that require further investigation and confirmation. The development of stent designed for the urinary tract, the selection of the appropriate substances combined with the appropriate experimental and clinical investigation would provide DESs acceptable for the urological practice.